Abcam, ab279292, Anti-PD-L1 antibody [CAL10] - Mouse IgG1 (Chimeric)

Size: 100µL / 1mL
Anti-PD-L1 antibody [CAL10] - Mouse IgG1 (Chimeric) (ab279292) is a mouse monoclonal antibody detecting PD-L1 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IHC-P, ICC/IF . Suitable for Human . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:CAL10,
Isotype:IgG1,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt (Intra), IHC-P, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-PD-L1 antibody [CAL10] - Mouse IgG1 (Chimeric) (ab279292) is a mouse recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Specificity confirmed
The specificity of Anti-PD-L1 antibody [CAL10] - Mouse IgG1 (Chimeric) (ab279292) has been confirmed by Western blot testing in CD274 Knockout A549 cell line,
ab267054
Other related products
We have a range of other formats of antibody clone [CAL10] also available for your convenience:
ab237726
, Carrier free -
ab251611
, Alexa Fluor® 647 -
ab267565
, ab279292,
ab279293
ab279294
, Carrier free -
ab279304
, Carrier free -
ab279305
, Carrier free -
ab279306
, Alexa Fluor® 555 -
ab307643

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.